Increased incidence of sensitization among patients with polycystic kidney disease following pretransplant blood transfusions.
Following pretreatment with at least 5 blood transfusions to 58 nontransfused uremic patients, 23 (40%) formed lymphocytotoxic antibodies against B cells and 9 (15%) against T cells as well. Significantly more (p less than 0.01) patients with polycystic kidney disease (6/16) formed T cell antibodies compared to patients with other diseases. The presence of antibodies delayed kidney transplantation, since significantly more (p less than 0.01) patients without antibodies (28 out of 35) received kidney grafts than patients with antibodies (9 out of 23). 5 patients received kidney grafts despite the occurrence of antibodies against donor B cells, but 3 of the patients lost their grafts within 1 month. In vitro lymphocyte subpopulations were studied in 4 patients before and after each of the planned blood transfusions. No persistent changes in lymphocyte responses to phytohemagglutinin and in mixed lymphocyte culture were seen. T cell subpopulations identified by monoclonal antibodies were unchanged, but the proportion of macrophages/monocytes (OKMl-positive cells) increased from 22 +/- 6 to 46 +/- 10% (p less than 0.05).
D000906:Antibodies / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D001803:Blood Transfusion; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology*; D007690:Polycystic Kidney Diseases / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology; D014511:Uremia / Q000276:immunology / Q000628:therapy
D000906:Antibodies